Loeys-Dietz syndrome type I and type II: clinical findings and novel mutations in two Italian patients
Although most of the studies reported an association between GLP-1 RA and increased residual gastric contents, evidence linking these medications to a statistically significant rise in regurgitation or aspiration events remains highly inconsistent
The study was sponsored by Eli Lilly and Company, the manufacturer of orforglipron and the injectable GLP-1, tirzepatide Side-effects were similar to other GLP-1s, including mild to moderate nausea, diarrhoea, constipation and bloating Its important to highlight that the study was quite small (just over 100 people in each arm of the study received active treatment), so more research is needed over a longer time period, says Dr Cork
Biscaldi, E., Ferrero, S., Fulcheri, E., Ragni, N., Remorgida, V., & Rollandi, G